Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain
The proposed methodologies allow for the analysis of the consistency of the manufacturing process and the variability from batch to batch.
Authors
- Alexis Oliva (ORCID: https://orcid.org/0000-0002-4661-4257)
- Matı́as Llabrés (ORCID: https://orcid.org/0000-0002-7984-6767)
- João Gonçalves (ORCID: https://orcid.org/0000-0002-1245-3715)
- Álvaro Santana‐Mayor (ORCID: https://orcid.org/0000-0003-1009-0460)
- Adrián Conde-Díaz (ORCID: https://orcid.org/0000-0003-2373-8676)
- Magdalena Echezarreta-López (ORCID: https://orcid.org/0000-0002-9989-1493)
- Shein‐Chung Chow
Institutions
- University of Lisbon (PT)
- Universidad de La Laguna (ES)
- Duke University (US)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-11-26
- DOI
- https://doi.org/10.3390/pharmaceutics16121520
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00